Does empagliflozin improve cardiac function and reduce fibrosis and inflammation in non-diabetic mice treated with doxorubicin?
Empagliflozin provides proof of concept for reducing doxorubicin-induced cardiotoxicity and improving cardiac function in non-diabetic models.
EMPA reduced ferroptosis, fibrosis, apoptosis and inflammation in doxorubicin-treated mice through the involvement of NLRP3 and MyD88-related pathways, resulting in significant improvements in cardiac functions. These findings provides the proof of concept for translational studies designed to reduce adverse cardiovascular outcomes in non-diabetic cancer patients treated with doxorubicin.
Quagliariello et al. (Fri,) studied this question.